INTRAVESICAL THERAPY OF SUPERFICIAL BLADDER TRANSITIONAL CELL-CARCINOMA WITH TUMOR-NECROSIS-FACTOR-ALPHA - PRELIMINARY-REPORT OF A PHASE I-II STUDY

被引:0
作者
SERRETTA, V
CORSELLI, G
PIAZZA, B
FRANKS, CR
PALMER, PA
ROEST, GJ
PAVONEMACALUSO, M
机构
[1] CIVIC HOSP BENFRATELLI,DEPT UROL,PALERMO,ITALY
[2] UNIV PALERMO,INST UROL,I-90134 PALERMO,ITALY
[3] EUROCETUS BV,AMSTERDAM,NETHERLANDS
关键词
TUMOR NECROSIS FACTOR; INTRAVESICAL THERAPY; BLADDER CARCINOMA;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A phase I-II trial of intravesical immunotherapy with tumor necrosis factor (TNF)-alpha in 24 patients affected by superficial bladder tumors is herein presented. Of these, 11 patients were submitted, at weekly intervals, after complete TUR, to 8 instillations of TNF-alpha at increasing doses from 50 to 600 mug. Tolerability was excellent. even at the highest dose. In a second group of 13 patients with a histologically proved papillary marker lesion, TNF-alpha was instilled at weekly intervals at the dose of 500 mug for 8 weeks. Three complete responses (23%) were obtained.
引用
收藏
页码:112 / 114
页数:3
相关论文
共 9 条
  • [1] RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA ADMINISTERED SUBCUTANEOUSLY OR INTRAMUSCULARLY FOR TREATMENT OF ADVANCED MALIGNANT DISEASE - A PHASE-I TRIAL
    AULITZKY, WE
    TILG, H
    GASTL, G
    MULL, R
    FLENER, R
    VOGEL, W
    HEROLD, M
    BERGER, M
    JUDMAIER, G
    HUBER, C
    [J]. EUROPEAN JOURNAL OF CANCER, 1991, 27 (04) : 462 - 467
  • [2] BOUFFIOUX C, 1991, SCAND J UROL NEPHR S, V138, P167
  • [3] CALABRESI F, 1990, TERAPIA MED ONCOLOGI, P80
  • [4] DAMMACCO F, 1988, RECENT ADV AUTOIMM 2, P157
  • [5] DENIS L, 1987, CANCER CHEMOTHER P S, V20, P67
  • [6] HARANAKA K, 1987, J BIOL RESP MODIF, V6, P379
  • [7] PAVONEMACALUSO M, 1989, EORTC GU MONOGRAPH, V6, P357
  • [8] SERRETTA V, 1988, ACTA UROL ITAL, V2, P85
  • [9] STERNBERG C, 1990, AM ASS CANCER RES AA, V31